Parabilis Medicines announced plans to raise up to $475 million through an initial public offering in the United States, filing to sell 25 million shares at a proposed price between $17 and $19 per share. The company intends to list its common stock on the Nasdaq exchange under the ticker PBLS.
In a separate but related financing, Regeneron Pharmaceuticals has agreed to acquire approximately $75 million of Parabilis Medicines' common stock through a concurrent private placement, according to the filing. The company disclosed how it expects to deploy the proceeds it raises from the public offering.
Planned allocations for the IPO proceeds include roughly $150 million earmarked for continued clinical development of zolucatetide specifically in desmoid tumors. An additional $120 million is slated to support ongoing clinical work for zolucatetide across a number of other indications. The filing also indicates that approximately $130 million of the proceeds would be used to advance Parabilis' broader pipeline of additional programs.
The company named a group of underwriters to manage the offering, with Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital serving in that capacity. The filing specifies the share count and price range but does not provide a definitive final offer price or expected closing date.
Parabilis' filing reiterates the capital allocation priorities among its lead candidate zolucatetide and its other pipeline programs, and it documents the concurrent private placement commitment from Regeneron. Details in the filing describe the number of shares proposed for sale and the proposed per-share price range but do not add further milestones or timelines tied to the funding uses.
Context and next steps
The registration statement establishes the parameters of the proposed public offering and identifies the financial institutions that will underwrite the deal. Further specifics about timing, final pricing, and other transaction mechanics will be determined as the offering progresses and disclosed in subsequent filings and statements.
This disclosure provides investors with the company's stated intentions for capital deployment, the involvement of a strategic investor through a private placement, and the underwriters who will handle distribution of the shares if the offering moves forward.